Src inhibition attenuates neuroinflammation via promoting p62 UFMylation-dependent microglial mitophagy
Biochemical Pharmacology · 2026-12 · 254 · 118503
DOI: 10.1016/j.bcp.2026.118503 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Pharmacology, 2026-12. Verfasst von Yi-Rong Dong und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Department of Pharmacology, Institute of Materia Medica, Chinese Acade…. Hauptthemen laut MEDLINE: Microglia, Mitophagy, src-Family Kinases, Neuroinflammatory Diseases. Die Arbeit nennt 46 Literaturangaben. Gefördert von: Innovation Fund, National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Src tyrosine kinase, a prototypical oncogene, has recently emerged as a critical modulator of neuroinflammation. However, the precise molecular mechanisms underlying its regulatory role remain poorly characterized. Herein, pharmacological inhibition of Src attenuated lipopolysaccharide-induced neuroinflammatory responses in both in vivo and in vitro experiments. Proteomic analysis identified that microglial mitophagy and p62 UFMylation were involved in Src-mediated neuroinflammation. Further studies demonstrated that Src inhibition reduced the phosphorylation of UFL1, the E3 ligase of UFM1 conjugation, which correlated with decreased UFMylation of p62. Notably, the function of p62 was regulated by a dynamic interplay between UFMylation and ubiquitination. Consequently, diminished p62 UFMylation competitively facilitated ubiquitination of p62 at the same residue. This led to p62 degradation and induced microglial mitophagy, ultimately alleviating neuroinflammation. Moreover, Src inhibition significantly ameliorated neuroinflammatory pathology and cognitive deficits in LPS-challenged mice, an effect attributed to p62 UFMylation-mediated microglial mitophagy. Collectively, our findings revealed that the Src-UFL1-p62 signaling axis governing microglial mitophagy and neuroimmune homeostasis, positioning Src kinase as a promising therapeutic target for Alzheimer's disease and related neuroinflammatory disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Department of Pharmacology, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, 1 Xian Nong Tan…
Förderung
- Innovation Fund
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Natural Science Foundation of Beijing Municipality
Zitieren
APA
Dong, Y. R., Wang, J. R., Yang, Y., Cao, S. P., Zhou, M. C., Zeng, S. X., Mi, H. Q., Wang, J. H., Zang, C. X., Li, F. F., Bao, X. Q., & Zhang, D. (2026). Src inhibition attenuates neuroinflammation via promoting p62 UFMylation-dependent microglial mitophagy. Biochemical Pharmacology, 254, 118503. https://doi.org/10.1016/j.bcp.2026.118503
Vancouver
Dong YR, Wang JR, Yang Y, Cao SP, Zhou MC, Zeng SX, et al. Src inhibition attenuates neuroinflammation via promoting p62 UFMylation-dependent microglial mitophagy. Biochemical Pharmacology. 2026;254:118503. doi:10.1016/j.bcp.2026.118503
BibTeX
@article{Dong2026,
author = {Dong, Yi-Rong and Wang, Jin-Rong and Yang, Yang and Cao, Shou-Peng and Zhou, Mei-Chuan and Zeng, Sen-Xiang and Mi, Hui-Qing and Wang, Jia-Hui and Zang, Cai-Xia and Li, Fang-Fang and Bao, Xiu-Qi and Zhang, Dan},
title = {Src inhibition attenuates neuroinflammation via promoting p62 UFMylation-dependent microglial mitophagy},
journal = {Biochemical Pharmacology},
year = {2026},
volume = {254},
pages = {118503},
doi = {10.1016/j.bcp.2026.118503}
}
EUVIMED